Clarivate Epidemiology’s coverage of Huntington’s disease (HD) in Europe comprises epidemiological estimates of key patient populations in 12 major mature pharmaceutical markets (Austria, Belgium,…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in the Americas (Argentina, Canada, Chile, Colombia, and Peru). We…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in emerging markets (Brazil, Russia, India, China, Mexico, Turkey, and…
Clarivate Epidemiology’s coverage of Huntington’s disease (HD) comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France…
Clarivate Epidemiology’s coverage of primary sclerosing cholangitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of malignant pleural mesothelioma (MPM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of mesothelioma comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
MARKET OUTLOOKPolycythemia vera (PV) is a rare hematological malignancy estimated to affect 50,000 people in the United States. Patients can be classified as having low- or high-risk PV, each of…
Clarivate Epidemiology’s coverage of postherpetic neuralgia (PHN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH…